Introduction can delay or prevent diabetes.
Together, these advances have set the stage for deInsulin-dependent diabetes mellitus (IDDM) is a multiveloping a complete molecular understanding of the factorial autoimmune disease for which susceptibility is pathogenesis of this autoimmune disease and for the determined by environmental and genetic factors. Inherdesign of rational and effective means of prevention. itance is polygenic, with the genotype of the major histoPrevention could then replace insulin therapy, which is compatibility complex (MHC) being the strongest geeffective but associated with long term renal, vascular, netic determinant. However, even in monozygotic twins, and retinal complications. the concordance rate is only 50% (Barnett et al., 1981) , indicating the importance of a number of as yet unidentified environmental factors (Castano and Eisenbarth,
The Role of the Major Histocompatibility Complex 1990). There is a north-south gradient in incidence of the Extensive sequencing of MHC class II alleles in man, disease with the highest incidence (1%-1.5% in Finland) being in northern Europe, with decreasing incidence the NOD mouse, and the Bio-breeding rat, as well as in more southerly and tropical locations. Although this the use of NOD mice transgenic for several MHC class suggests the effect of infectious agents, in the nonobese II molecules, has revealed a complex interplay between diabetic (NOD) mouse, germ-free NOD mice have the alleles of the two major isotypes of MHC class II molehighest incidence (nearly 100%) that has been seen in cules (HLA [human leukocyte antigen] DR and DQ in any NOD colony. man, and I-A and I-E in the mouse]) (Wicker et al., 1995) . While MHC class II genotype is one of the strongest Susceptibility to type I diabetes is most strongly deterfactors determining susceptibility to IDDM, it has long mined by DQ and I-A␤ chain alleles that encode serine, been apparent that susceptibility at MHC class II is a alanine, or valine at position 57 on both chromosomes necessary but not sufficient predisposing genetic factor.
( Acha-Orbea and McDevitt, 1987; Todd et al., 1987) . Microsatellite analyses of genome-wide polymorphisms DQ␤ and I-A␤ position 57 aspartic acid positive alleles in multiplex IDDM families and in NOD crosses with mediate resistance to IDDM, which varies in degree with nonsusceptible strains have identified many other gethe sequence of other residues in the DQ␣ and ␤ chains. netic regions that also influence susceptibility. Thus, in Expression of I-E (␤ chain position 57 aspartic acid posithe NOD mouse there are at least 15 other regions on tive) in the NOD mouse, and of DR B1 chains expressing 11 other chromosomes that contribute to genetic predisaspartic acid at position 57, also mediates varying deposition (Vyse and Todd, 1996 [this issue of Cell] ). In grees of resistance to type I IDDM. Thus, HLA DR B1 man, linkage studies have suggested an even larger number (as many as 19) genetic regions determining alleles lacking aspartic acid at position 57 in Japanese IDDM susceptibility. For the most part, the genes depatients are associated with a higher degree of susceptitermining susceptibility in each of these chromosomal bility than Asp-57( ϩ ) HLA-DR B1 alleles (Ikegami et al., regions have yet to be identified. Several of these re-1989, Diabetes, abstract). There is also evidence that gions also influence susceptibility to a murine counter-MHC class I genotype may have a similar modifying part of systemic lupus erythematosus and to a murine effect (Ikegami et al., 1993) . model of multiple sclerosis (Vyse and Todd, 1996) .
These associations have now been extensively tested IDDM in animal models is T cell mediated and requires in many studies (Nepom and Erlich, 1991) and several the participation of both CD8 ϩ , class I MHC restricted exceptions have been noted. (Ikegami et al., 1989, Diaand CD4 ϩ , class II MHC restricted T cells (Wicker et al., betes, abstract; Erlich et al., 1993) . Results from these 1995). Extensive studies in rodent models have failed studies indicate that polymorphisms in the DQ␣ chain, to identify the origins of the autoreactivity in IDDM, but elsewhere in the DQ␤ chain, and in the DR B1 chain demonstrate the importance of a number (8-10) of islet play an important modifying role. In some populations ␤ cell-expressed proteins that are the targets of the this can be shown to be due to similar sequence polyautoimmune process in this disease (Table 1) ) with bility (Cucca et al., 1995) (Table 2 , this study). a mutation to aspartic acid at position 57 in A ␤ have a Peptide elution studies by Ramensee et al. (1995) and decreased or zero incidence of IDDM (see references Reich et al. (1994) have provided indirect support for in Quartey-Papafio et al., 1995) . Cell transfer studies the concept that HLA-DQ ,-DR, and I-A polymorphisms suggest this decreased incidence is the result of a preaffect susceptibility to IDDM by selectively affecting the dominant Th2 response to islet cell antigens (Singer, et nature of the peptides presented to T cells by these al., 1993), but definitive proof for this interpretation is class II molecules. These authors showed that peptides yet to be published. Competition between susceptible eluted from HLA-DR alleles that have or lack aspartic and resistant alleles for binding a critical diabetogenic acid at HLA-DR␤57 bind overlapping but distinct sets peptide has been postulated as an alternative explanaof peptides. Thus HLA DR B1-04 alleles lacking aspartic tion for these data (Nepom, 1990; Quartey-Papafio et acid at position 57 bind peptides with glutamic acid or al., 1995). Support for the former hypothesis is seen in aspartic acid at position P9 in the peptide (Table 3 ). This studies of IDDM families (Thai and Eisenbarth, 1993) . is presumably because the absence of aspartic acid at Although DQB1 0602 (an IDDM-resistant allele) positive DR ␤1 position 57 leaves a conserved arginine at DR␣79 siblings of diabetics rarely develop diabetes, they can free to interact with a negative charge at the carboxyl produce high titers of autoantibodies to several islet terminus of the peptide (Stern et al., 1994; Wucherpfen- cell antigens. This indicates that resistant alleles do not nig and Strominger, 1995). In position 57 aspartic acid cause resistance by inducing more complete self-tolerpositive alleles, Asp-57 forms a salt bridge with ␣-Argance to islet cell antigens than do the susceptible DQ␤1 79, and peptides with a negative charge at or near the alleles. (Nepom, 1990; Erlich et al., 1993) . carboxyl terminus of the peptide are not bound to any
The results cited above bring us tantalizingly close appreciable degree. (These data are derived from amino to understanding how susceptible and resistant alleles acid sequence studies of complex mixtures of peptides mediate their effects. The issues raised can only be eluted from the respective alleles. It is likely that both resolved when peptide epitopes derived from critical types of allele, which are nearly identical in sequence islet cell autoantigens have been identified and characelsewhere in the DR ␤1 chain, will also bind many of the terized with respect to their ability to elicit insulitis and same peptides).
IDDM-inducing T cells. The long list of antigens that are the target of an autoimmune response in both mouse and man (see below) means that the peptide epitopes itis, first seen at 4-6 weeks of age, is characterized by an accumulation of macrophages, dendritic cells, and recognition of GAD (and insulin, see below) occurs early in the disease process, and that anti-GAD reactivity may B and T lymphocytes that enter the periductal areas but mediate initial events associated with intra-insulitis. remain outside of the islet proper. At later time points, NOD mice remain protected from diabetes when treated intra-insulitis develops and is characterized by the direct with GAD either at an age preceding islet inflammation invasion of the islets by infiltrating cells, and is depenor when exhibiting extensive intra-insulitis, providing dent on the recognition of ␤ cell antigen(s) (Wicker et functional evidence that GAD may have a critical role in al., 1992). A temporal analysis of ␤ cell reactivity in NOD the disease process (Kaufman et al., 1993; Tisch et al., mice suggests that only a few autoantigens are targeted 1993; Elliott et al., 1994) . In these studies protection, in the early stages (Kaufman et al., 1993; Tisch et al., at least in part, appears to be mediated through the 1993). As intra-insulitis progresses, additional ␤ cell deinduction of GAD-specific regulatory T cells that secrete struction occurs, apparently resulting in the sensitizalymphokines that nonspecifically suppress the diabetotion and recruitment of other ␤ cell-specific T cells found genic response. To determine the relative contribution in the periphery. Intra-insulitis per se, however, does and precise role of anti-GAD reactivity in the disease not appear to be sufficient to drive the response to an process, experiments need to be done in which GADovert diabetic state. This is suggested by studies in NOD specific T cells are selectively tolerized by clonal delemice transgenic for a pathogenic T cell receptor (TCR) tion/anergy induction, to detect the effect this has on that exhibit a highly aggressive form of intra-insulitis development of insulitis and IDDM. beginning abruptly at 3-4 weeks of age, yet the time of
Insulin is another ␤ cell autoantigen that appears to onset (18-20 weeks) and the frequency of overt diabetes have a critical role in the diabetogenic response. Antiin these animals is only marginally enhanced (Katz et insulin autoantibodies can be detected in ‫%05ف‬ of real., 1993a). These 3 week and 18-20 week checkpoints cent-onset IDDM subjects and are most frequent in may reflect the requirement for additional events in order younger children who exhibit an enhanced rate of ␤ cell to initiate insulitis and then to progress to overt diabetes.
destruction (Castano and Eisenbarth, 1990) . Insulin is a These events may depend on the outcome of interackey T cell target in that insulin B chain-specific CD4 ϩ T tions occurring between effector and regulatory T cells cell clones can accelerate diabetes in young NOD mice (see below) or sequential targeting of specific ␤ cell or adoptively transfer disease in NOD-scid mice (Daniel autoantigens, or both. et al., 1995) . Furthermore, oral or parenteral treatment Only in the past 5-7 years has the identity of most of of young NOD mice with whole insulin or insulin B chain, the ␤ cell autoantigens been determined. Despite this respectively, can protect animals from diabetes (Zhang progress, little is known about the role these autoantiet al., 1991; Muir et al., 1995) . This protection again gens may play in the disease process, i.e. whether they appears to be partially mediated through the induction are in fact pathogenic. At present, conclusions regarding of immunoregulatory T cells, so that the relative contrithe possible role/importance of a given ␤ cell autoantibution of anti-insulin reactivity to the disease process gen in IDDM are based upon two sources: first, observed is still not clear. In contrast to young NOD mice treated correlations between autoantibody reactivity (and more with GAD, animals receiving insulin or insulin-B chain recently T cell reactivity) and disease progression in continue to exhibit intra-insulitis, suggesting that antiman and in NOD mice, and second, studies determining insulin reactivity may be necessary for more distal whether the diabetogenic response in NOD mice can events in disease progression. be modulated following treatment with the autoantigen Additional autoreactivity seen during the development or transfer of specific T cell clones, or both.
of human diabetes includes antibodies to two tryptic Using the above criteria, glutamic acid decarboxylase fragments with molecular masses of 37 and 40 kDa, (GAD) is one of only three critical ␤ cell autoantigens.
derived from a ␤ cell antigen. Autoantibodies against GAD is an enzmye with two isoforms, GAD65 and these fragments have been detected in 60% of newly GAD67, that catalyze the biosynthesis of the neurotransdiagnosed individuals and appear to identify a subgroup mitter ␥-aminobutyric acid. The presence of anti-GAD of IDDM patients who rapidly progress to diabetes antibodies in the sera of prediabetic individuals has (Christie et al., 1994) . The recent discovery that the two proven to be a reliable predictive marker for progression tryptic fragments are derived from the putative tyrosine to overt diabetes (Baekkeskov et al., 1990; Hagopian phosphatase IA-2 should aid in assessing T cell reactivet al., 1993). T cell reactivity in IDDM patients can be ity to the autoantigen and its possible role in the diabetodetected to a region of GAD that contains homology to genic response (Passini et al., 1995) . A protein desigthe Coxsackie B P2-C viral protein (Atkinson et al., 1994) . nated as p69 has been shown to be an additional target The fact that Coxsackie B viral infections have been of autoantibodies found in IDDM patients (Pietropaolo implicated in cases of IDDM has led to the intriguing et al. , 1993) . hypothesis that recognition of GAD may be stimulated Autoantibodies and T cell reactivity specific for HSP60 in some instances by a response to the virus.
have also been detected in NOD mice. Whether HSP60 NOD mice also exhibit antibody reactivity to GAD (and is targeted in the human diabetogenic response remains to insulin). Responses to GAD and insulin (but not to unclear. However, treatment of NOD mice with HSP60 other ␤ cell autoantigens such as HSP60, peripherin, protects animals from disease (Elias et al., 1991 ). Moreand carboxypeptidase H) can be detected in animals at over, it has been reported that treatment of hyperglycean age when minimal histological signs of islet inflammamic NOD mice with an HSP60-specific peptide can reestion are observed (Kaufman et al., 1993; Tisch et al., tablish euglycemic blood levels (Elias and Cohen, 1994) . 1993). Anti-GAD reactivity is seen in some NOD mice Finally, HSP60-specific CD4 ϩ T cell lines have been that exhibit extensive intra-insulitis, yet remain diabetes shown to accelerate or block disease in NOD recipients (Elias et al., 1991) . free . These observations suggest that Undefined components of the ␤ cell secretory granule exacerbates the development of diabetes and that monoclonal antibodies specific for Th1-derived cytohave been shown to be targeted by pathogenic CD4 ϩ T cell clones established from NOD mice (Haskins and kines block the development of the disease (Rabinovitch, 1994 ). In addition, murine ␤ cell-specific T cell McDuffie, 1990 ) and by CD4 ϩ T cell clones from IDDM patients (Roep et al., 1990) .
clones that exhibit a Th1 phenotype can efficiently transfer disease in syngeneic young NOD recipients (Haskins Thus, a number of ␤ cell autoantigens are recognized during the diabetogenic process. The task at hand is to and McDuffie, 1990; Shimizu et al., 1993; Katz et al., 1995) . Th2 cells, which are characterized by the secredistinguish those antigens that play a primary role in initiating the autoimmune process from those autoantition of IL-4, IL-5, IL-6, IL-10, and IL-13 and primarily support humoral mediated immunity, appear to have a gens that elicit an autoimmune response as a secondary event due to local inflammation. This might be achieved down-regulatory role in IDDM. Administration of IL-4 (Rapoport et al., 1993 ) or IL-10 (Pennline et al., 1994 , in animal studies in which the T cells specific for a given autoantigen are selectively tolerized, and the effect this both of which promote Th2 development and function, protects NOD mice from diabetes. In addition, purified has on insulitis and IDDM then determined. A sequential study over time of T cell reactivity in HLA identical sib-T cells with a CD45RC lo (Th2-like) phenotype prevent an induced form of diabetes in rats (Fowell and Mason, lings of diabetics, and in recent onset IDDM patients, may also provide further insight into the relative impor-1993).
Several studies indicate that a functional imbalance tance of a given autoantigen.
between the two Th cell subsets is a key determinant in establishing islet pathology. A high ratio of IFN␥/IL-4 The T Cell Response in IDDM Studies primarily in the NOD mouse have attempted to producing T cells can normally be detected in infiltrates leading to the destruction of islets grafted under the determine whether the repertoire of infiltrating T cells exhibit V␣ or V␤ restriction. To date, there has been no kidney capsule in NOD mice (Shehadeh et al., 1993) . In contrast, grafted islets in NOD mice containing infiltrates consistent evidence indicating that restriction in V␣ or V␤ usage exists among T cells found in the pancreas.
with a lower ratio of IFN␥/IL-4 producing T cells (as a result of receiving Freund's adjuvant) remain intact. However, a recent study has reported that, in two diabetic patients, preferential usage of the V␤7 gene was Furthermore, a recent study has suggested that an inverse relationship exists between humoral reactivity to detected in the infiltrating T cells (Conrad et al., 1994) . This restriction was argued to be the result of T cell GAD and risk for IDDM in prediabetic patient populations (Harrison et al., 1993) . activation by an unidentified infectious agent encoding a superantigen within the islets.
The events that modulate the balance between the two Th subsets in IDDM are still a matter of speculation. Studies with NOD mice deficient in MHC class I or class II expression-and in turn devoid of CD8 ϩ on CD4 ϩ
Factors that may have quantitative or qualitative effects on T cell activation such as the density of MHC/peptide T cells, respectively-have demonstrated that both T cell subsets are required for islet infiltration and subsecomplexes on the surface of APCs (Pfeiffer et al., 1995) , TCR affinity/avidity for the binary complex, or interacquent ␤ cell destruction (Katz et al., 1993b; Serreze et al., 1994; Wicker et al., 1994) . However, the respective tions between costimulatory molecules (Lenschow et al., 1995) may lead to preferential development of Th1 contribution of each subset is presently not clear. Numerous studies have shown that CD4 ϩ T cells alone are cells in IDDM. It is also conceivable that one or more of the several non-MHC genes that confer IDDM susceptifar more efficient in the adoptive transfer of disease than CD8 ϩ T cells. The effectiveness of CD4 ϩ T cells in bility may be associated with some aspect of Th cell subset development (Scott et al., 1994) . transferring disease is most likely due to the secretion of lymphokines such as IFN␥ and TNF␣ that are directly
To view the regulation of the disease process strictly in terms of Th1 and Th2 subsets is undoubtly an overtoxic to ␤ cells and that recruit nonspecific effector cells to amplify the response. CD8 ϩ T cells on the other hand, simplification. For example, CD4 ϩ Th1 autoreactive T cell clones have been established from NOD mice that may have a more restricted role in the disease process. It has been suggested that CD8 ϩ T cells are required to secrete an unknown factor which can suppress the adoptive transfer of diabetes (Akhtar et al., 1995) . In initiate ␤ cell injury, which in turn could lead to the priming of CD4 ϩ T cells and subsequent amplification addition, T cells expressing a diabetogenic TCR and cultured under conditions to promote Th2 development of the response (Wicker et al., 1994) . The lack of insulitis in class I-deficient NOD mice and the appearance of are unable to mediate protection in NOD recipients (Katz et al., 1995) . CD8 ϩ T cells have also been shown to CD8 ϩ T cells in the islets prior to CD4 ϩ T cells (Jarpe et al., 1991) support this notion.
exhibit Th1-and Th2-like phenotypes, and the contribution of cytokines secreted by non-T cells must certainly CD4 ϩ T cell dominance in the diabetic process may be considered. The development of a given Th cell subreflect the critical role this subset has in regulating the set and, in turn, the outcome of the diabetogenic reimmune system. CD4 ϩ T cells can be divided into distinct sponse undoubtedly involve the interplay of a number subsets based on their cytokine profiles. These subsets of cell types and factors. of Th cells oppose one another through reciprocal downregulatory effects mediated by their respective cytokines. Th1 cells, which secrete IL-2, IFN␥, and TNF␣ Immunotherapy Early attempts to prevent IDDM typically relied on immuand predominantly support cell-mediated immunity, are believed to be the primary CD4 ϩ T cells mediating IDDM. nosuppressive drugs (cyclosporine) or drugs that indiscriminantly inhibit cell proliferation (imuran), often leadThis is supported by animal studies showing that administration of cytokines that promote Th1 development ing to serious side effects. Therefore, a great deal of effort has focused on selectively targeting those T cells Although antigen-specific immunotherapy appears to be a promising method to prevent IDDM, it is most likely involved in the disease process. One general approach has been to employ monoclonal antibodies specific for that a combination of approaches may prove to be more generally effective. Thus, active suppression by antigenmolecules expressed by the effector T cell population. Monoclonal antibodies specific for CD4 (Shizuru et al., induced regulatory T cells may be enhanced in concert with antibodies targeting cytokines required for Th1 de-1988) and CD3, a component of TCRs (Chatenoud et al., 1993) , have been shown to be effective in the prevenvelopment and function. Furthermore, as additional ␤ cell autoantigens are identified and shown to have a tion and treatment, respectively, of diabetes in NOD mice. Similarly, prediabetic NOD mice are protected role in the disease process, therapy might employ a number of autoantigens to target the polyclonal populafrom disease when treated with antibodies that interfere with antigen recognition (anti-class II, Boitard et al., tion of autoreactive T cells, thereby increasing the likelihood of successful treatment. 1988; anti-TCR, Sempe et al., 1991) , cellular activation (anti-B7; Lenschow et al., 1995) , and homing to the panEven if safe, effective, and long lasting immunotherapies are developed, their application is a formidable creas (anti-L selectin and anti-VLA-4; Yang et al., 1993) . Finally, antibodies targeting cytokines associated with challenge. Only 15% of new cases of IDDM occur in families with a previous case in the kindred. Overt diabeTh1 activity (anti-IFN␥, anti-TNF␣, and anti-IL-12; Rabinovitch, 1994) have been able to prevent disease in predites develops only when ␤ cell destruction is nearly complete, and the patient is asymptomatic for months or abetic NOD mice. In general, however, the applicability of antibodies specific for these "immune-related moleyears until that point is reached. Immunotherapy thus must be preventive, which requires inexpensive, accucules" to human IDDM is limited by the side effects of chronic administration, such as immunogenicity, and rate genetic, autoantibody, and T cell screening techniques. Given the large number of islet cell autoantigens the lack of selectivity.
An alternative approach is to devise protocols in which now available and the rapid progress in identifying genetic susceptibility markers, such screening techniques immunomodulation can be selectively applied through the use of a specific antigen/peptide. Recently, it has should soon be feasible. Hopefully, effective methods of prevention will promote widespread population been demonstrated that insulin, when adminstered prior to the onset of diabetes, can delay or prevent disease screening and the application of preventive therapy. in individuals at high risk for IDDM (Keller et al., 1993 ). The precise mechanism by which protection is mediated
